The scope for pneumococcal vaccines that do not prevent transmission

被引：4
作者：
Flasche, Stefan [1 ]
机构：
[1] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Keppel St, London WC1E 7HT, England
来源：
VACCINE | 2017年 / 35卷 / 45期
关键词：
S; pneumoniae; Vaccine; Replacement; Herd protection; STREPTOCOCCUS-PNEUMONIAE; CONJUGATE VACCINE; DISEASE;
D O I：
10.1016/j.vaccine.2017.09.073
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The pneumococcal vaccine pipeline holds candidates developed with the aim to prevent the majority if not all pneumococcal disease. Herd protection is a critical component of the overall impact of current pneumococcal conjugate vaccines (PCVs) and is a prerequisite for disease elimination through an infant vaccination programme. We assessed the scope of a hypothetical pneumococcal vaccine candidate (HPVC) with high clinical efficacy against all pneumococci but that fails to induce such indirect protection. We found that, despite a lack of impact on unvaccinated individuals, HPVC use in infancy may offer similar or superior impact among young children if compared to current PCVs. Hence, it could provide a more affordable alternative to PCVs in particular in settings where most pneumococcal disease is concentrated in children. (C) 2017 Elsevier Ltd. All rights reserved.
引用
收藏
页码：6043 / 6046
页数：4
相关论文
共 15 条
  • [1] Status of research and development of pediatric vaccines for Streptococcus pneumoniae
    Alderson, Mark R.
    [J]. VACCINE, 2016, 34 (26) : 2959 - 2961
  • [2] [Anonymous], 1999, Wkly Epidemiol Rec, V74, P177
  • [3] Serotype-Specific Changes in Invasive Pneumococcal Disease after Pneumococcal Conjugate Vaccine Introduction: A Pooled Analysis of Multiple Surveillance Sites
    Feikin, Daniel R.
    Kagucia, Eunice W.
    Loo, Jennifer D.
    Link-Gelles, Ruth
    Puhan, Milo A.
    Cherian, Thomas
    Levine, Orin S.
    Whitney, Cynthia G.
    O'Brien, Katherine L.
    Moore, Matthew R.
    [J]. PLOS MEDICINE, 2013, 10 (09)
  • [4] Assessing the efficiency of catch-up campaigns for the introduction of pneumococcal conjugate vaccine: a modelling study based on data from PCV10 introduction in Kilifi, Kenya
    Flasche, Stefan
    Ojal, John
    de Waroux, Olivier Le Polain
    Otiende, Mark
    O'Brien, Katherine L.
    Kiti, Moses
    Nokes, D. James
    Edmunds, W. John
    Scott, J. Anthony G.
    [J]. BMC MEDICINE, 2017, 15
  • [5] The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries
    Flasche, Stefan
    Van Hoek, Albert Jan
    Goldblatt, David
    Edmunds, W. John
    O'Brien, Katherine L.
    Scott, J. Anthony G.
    Miller, Elizabeth
    [J]. PLOS MEDICINE, 2015, 12 (06):
  • [6] Gavi The Vaccine Aliance, 2017, TRANS PROC
  • [7] International Vaccine Access Center - Johns Hokins Bloomberg School of Public Health, GLOB PCV INTR STAT
  • [8] Herd protection induced by pneumococcal conjugate vaccine
    Klugman, Keith P.
    [J]. LANCET GLOBAL HEALTH, 2014, 2 (07): : E365 - E366
  • [9] Invasive Pneumococcal Disease 3 Years after Introduction of 10-Valent Pneumococcal Conjugate Vaccine, the Netherlands
    Knol, Mirjam J.
    Wagenvoort, Gertjan H. J.
    Sanders, Elisabeth A. M.
    Elberse, Karin
    Vlaminckx, Bart J.
    de Melker, Hester E.
    van der Ende, Arie
    [J]. EMERGING INFECTIOUS DISEASES, 2015, 21 (11) : 2040 - 2044
  • [10] Mackenzie GA, 2016, LANCET INFECT DIS, V3099, P1
12